Elamipretide (SS-31)
SS-31 · Bendavia
Designed to concentrate at the inner mitochondrial membrane and influence membrane and oxidative function.
Mechanism
Mitochondria-targeting cardiolipin-interacting tetrapeptide
Protocol studied in research
Study design shown in plain language. This is not a personal dosing recommendation.
Multiple mitochondrial and cardiac-disease populations
Community-Reported Research Schedules
Descriptive community patterns are separated from clearly labeled trial-derived reference rows. Neither is personal dosing guidance.
| Research context or phase | Amount per administration | Schedule total | Frequency | Timing | Administration | Evidence level |
|---|---|---|---|---|---|---|
| Reported daily research range | 4–40 mg | 4–40 mg/day | Once daily | Consistent daily time | Subcutaneous | Community-reported |
Important: Repetition in online communities does not establish product identity, safety, effectiveness, or an appropriate exposure. Route-specific schedules, half-life estimates and reported cycle lengths are shown for comparison only.
Example Reconstitution Protocol
A hypothetical concentration calculation for literacy and review—not preparation, administration, or dosing instructions.
Important: Vial strength, diluent identity, compatibility, sterility, stability and beyond-use time are product-specific. Never infer them from this arithmetic example. Use manufacturer, pharmacy, study, or licensed-clinician instructions for an actual preparation.
Cycle & Supplies Planning
Phase-by-phase cycle math showing how long a vial lasts and the estimated supplies required.
Cycle Structure
| Phase | Amount | Frequency | Weekly total |
|---|---|---|---|
| Selected planning schedule | 4–40 mg | Once daily | 28–280 mg/week |
Peptide Vials
| Cycle | Total compound | Vials needed | How long one vial lasts |
|---|---|---|---|
| 4 weeks | 112–1120 mg | 12–112 × 10 mg | 0.25–2.5 administrations |
| 8 weeks | 224–2240 mg | 23–224 × 10 mg | 0.25–2.5 administrations |
| 12 weeks | 336–3360 mg | 34–336 × 10 mg | 0.25–2.5 administrations |
Bacteriostatic Water
| Cycle | Total water used | 10 mL bottles needed |
|---|---|---|
| 4 weeks | 12–112 mL | 2–12 × 10 mL |
| 8 weeks | 23–224 mL | 3–23 × 10 mL |
| 12 weeks | 34–336 mL | 4–34 × 10 mL |
Insulin Syringes (U-100)
| Cycle | Administrations | Syringes needed |
|---|---|---|
| 4 weeks | 28 | 28 |
| 8 weeks | 56 | 56 |
| 12 weeks | 84 | 84 |
Ranges reflect the low and high ends of the displayed community schedule. Vials and 10 mL water bottles are rounded up; one new U-100 syringe is counted per subcutaneous administration.
Planning boundary: These are arithmetic examples based on the displayed research schedule—not personal dosing or purchasing instructions. Confirm product format, compatibility, route, sterility, storage, and discard timing independently. U-100 units measure liquid volume, not potency.
Safety signal
Efficacy has varied by indication; injection-site reactions are common in subcutaneous studies.
Reported doses describe either a specific study or an unverified community pattern. Neither is personal medical guidance.